Analysis NeuroVive: Cash injection gets new trial going

NeuroVive has taken constructive steps during the spring. A capital raise of SEK 108m has enabled the start of a phase I trial in mitochondrial diseases. The share price is subdued, however we see some potential catalysts for higher valuation.

Read the full report (Swedish) here.